Quadrant Capital Group LLC Acquires 30,346 Shares of Kenvue Inc. $KVUE

Quadrant Capital Group LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 872.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,824 shares of the company’s stock after buying an additional 30,346 shares during the quarter. Quadrant Capital Group LLC’s holdings in Kenvue were worth $708,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in KVUE. Renaissance Capital LLC boosted its stake in Kenvue by 8.3% during the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after buying an additional 48,267 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Kenvue by 80.7% during the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after purchasing an additional 16,164 shares during the period. Arlington Partners LLC bought a new position in Kenvue during the 2nd quarter valued at about $2,110,000. Cornell Pochily Investment Advisors Inc. raised its position in Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after purchasing an additional 19,609 shares during the period. Finally, AG2R LA Mondiale Gestion D Actifs purchased a new stake in Kenvue in the 1st quarter worth about $1,725,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KVUE. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Citigroup reduced their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Canaccord Genuity Group reissued a “hold” rating and set a $15.00 target price (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $20.23.

View Our Latest Stock Analysis on KVUE

Kenvue Trading Down 0.6%

Shares of NYSE KVUE opened at $17.25 on Tuesday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The business has a fifty day moving average price of $16.07 and a 200 day moving average price of $19.49. The stock has a market capitalization of $33.04 billion, a P/E ratio of 22.99 and a beta of 0.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s payout ratio is 110.67%.

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Featured Stories

• Five stocks we like better than Kenvue
• Should You Invest in Penny Stocks?
• Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
• 3 Defense Stocks Set to Benefit From Increased Military Spending
• Congress Beat the Market Again—Here Are the 3 Stocks They Bought
• Stock Market Upgrades: What Are They?
• Go on a Shopping Spree With 3 Top Retail ETFs

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).